Agreements reached under this partnership
Business Alliances- 1
AbbVie will acquire exclusive worldwide development and commercialization rights to NXE0033744 for inflammatory bowel disease (IBD).
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
If the transaction is completed by 31 December 2026, the US$100 million upfront payment is expected to have a material positive impact on Nxera's revenue and is scheduled to be recognized as revenue in the fourth quarter of the fiscal year ending December 2026.
| Item | Details |
|---|---|
| Name of alliance partner | AbbVie Inc. |
| Alliance partner's business activities | Deep expertise and a strong track record in immune-mediated diseases and global clinical development |
| Type of alliance | Business Alliances |
| Details of the alliance | AbbVie will acquire exclusive worldwide development and commercialization rights to NXE0033744 for inflammatory bowel disease (IBD). |
| Contract Date | 4 November 2026 |
| Impact on Business Performance | If the transaction is completed by 31 December 2026, the US$100 million upfront payment is expected to have a material positive impact on Nxera's revenue and is scheduled to be recognized as revenue in the fourth quarter of the fiscal year ending December 2026. |
Items this document does not state (17)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company determined that AbbVie is an appropriate partner for advancing NXE0033744 as an effective treatment for patients with inflammatory bowel disease, given its deep expertise and strong track record in immune-mediated diseases and global clinical development. The company also expects the upfront payment and other proceeds to strengthen its financial position.